BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 24067491)

  • 1. Leukemic evolution of donor-derived cells harboring IDH2 and DNMT3A mutations after allogeneic stem cell transplantation.
    Yasuda T; Ueno T; Fukumura K; Yamato A; Ando M; Yamaguchi H; Soda M; Kawazu M; Sai E; Yamashita Y; Murata M; Kiyoi H; Naoe T; Mano H
    Leukemia; 2014 Feb; 28(2):426-8. PubMed ID: 24067491
    [No Abstract]   [Full Text] [Related]  

  • 2. Droplet digital polymerase chain reaction for DNMT3A and IDH1/2 mutations to improve early detection of acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation.
    Brambati C; Galbiati S; Xue E; Toffalori C; Crucitti L; Greco R; Sala E; Crippa A; Chiesa L; Soriani N; Mazzi B; Tresoldi C; Stanghellini MT; Peccatori J; Carrabba MG; Bernardi M; Ferrari M; Lampasona V; Ciceri F; Vago L
    Haematologica; 2016 Apr; 101(4):e157-61. PubMed ID: 26703962
    [No Abstract]   [Full Text] [Related]  

  • 3. Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents.
    DiNardo CD; Patel KP; Garcia-Manero G; Luthra R; Pierce S; Borthakur G; Jabbour E; Kadia T; Pemmaraju N; Konopleva M; Faderl S; Cortes J; Kantarjian HM; Ravandi F
    Leuk Lymphoma; 2014 Aug; 55(8):1925-9. PubMed ID: 24138309
    [No Abstract]   [Full Text] [Related]  

  • 4. Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: a report from the Children's Oncology Group.
    Ho PA; Kutny MA; Alonzo TA; Gerbing RB; Joaquin J; Raimondi SC; Gamis AS; Meshinchi S
    Pediatr Blood Cancer; 2011 Aug; 57(2):204-9. PubMed ID: 21504050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adult acute myeloid leukemia with trisomy 11 as the sole abnormality is characterized by the presence of five distinct gene mutations: MLL-PTD, DNMT3A, U2AF1, FLT3-ITD and IDH2.
    Eisfeld AK; Kohlschmidt J; Mrózek K; Blachly JS; Nicolet D; Kroll K; Orwick S; Carroll AJ; Stone RM; de la Chapelle A; Byrd JC; Bloomfield CD
    Leukemia; 2016 Nov; 30(11):2254-2258. PubMed ID: 27435003
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparative examination of various PCR-based methods for DNMT3A and IDH1/2 mutations identification in acute myeloid leukemia.
    Berenstein R; Blau IW; Kar A; Cay R; Sindram A; Seide C; Blau O
    J Exp Clin Cancer Res; 2014 May; 33(1):44. PubMed ID: 24887327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of high-resolution melting analysis with direct sequencing for the detection of recurrent mutations in DNA methyltransferase 3A and isocitrate dehydrogenase 1 and 2 genes in acute myeloid leukemia patients.
    Gorniak P; Ejduk A; Borg K; Makuch-Lasica H; Nowak G; Lech-Maranda E; Prochorec-Sobieszek M; Warzocha K; Juszczynski P
    Eur J Haematol; 2016 Feb; 96(2):181-7. PubMed ID: 25891904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dnmt3a loss and Idh2 neomorphic mutations mutually potentiate malignant hematopoiesis.
    Zhang X; Wang X; Wang XQD; Su J; Putluri N; Zhou T; Qu Y; Jeong M; Guzman A; Rosas C; Huang Y; Sreekumar A; Li W; Goodell MA
    Blood; 2020 Mar; 135(11):845-856. PubMed ID: 31932841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GADD45A methylation predicts poor overall survival in acute myeloid leukemia and is associated with IDH1/2 and DNMT3A mutations.
    Perugini M; Iarossi DG; Kok CH; Cummings N; Diakiw SM; Brown AL; Danner S; Bardy P; Bik To L; Wei AH; Lewis ID; D'Andrea RJ
    Leukemia; 2013 Jul; 27(7):1588-92. PubMed ID: 23187294
    [No Abstract]   [Full Text] [Related]  

  • 10. DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies.
    Im AP; Sehgal AR; Carroll MP; Smith BD; Tefferi A; Johnson DE; Boyiadzis M
    Leukemia; 2014 Sep; 28(9):1774-83. PubMed ID: 24699305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia.
    Chan SM; Majeti R
    Int J Hematol; 2013 Dec; 98(6):648-57. PubMed ID: 23949914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association.
    Debarri H; Lebon D; Roumier C; Cheok M; Marceau-Renaut A; Nibourel O; Geffroy S; Helevaut N; Rousselot P; Gruson B; Gardin C; Chretien ML; Sebda S; Figeac M; Berthon C; Quesnel B; Boissel N; Castaigne S; Dombret H; Renneville A; Preudhomme C
    Oncotarget; 2015 Dec; 6(39):42345-53. PubMed ID: 26486081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FLT3-ITD Compared with DNMT3A R882 Mutation Is a More Powerful Independent Inferior Prognostic Factor in Adult Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study.
    Ardestani MT; Kazemi A; Chahardouli B; Mohammadi S; Nikbakht M; Rostami S; Jalili M; Vaezi M; Alimoghaddam K; Ghavamzadeh A
    Turk J Haematol; 2018 Aug; 35(3):158-167. PubMed ID: 29786546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers.
    Glass JL; Hassane D; Wouters BJ; Kunimoto H; Avellino R; Garrett-Bakelman FE; Guryanova OA; Bowman R; Redlich S; Intlekofer AM; Meydan C; Qin T; Fall M; Alonso A; Guzman ML; Valk PJM; Thompson CB; Levine R; Elemento O; Delwel R; Melnick A; Figueroa ME
    Cancer Discov; 2017 Aug; 7(8):868-883. PubMed ID: 28408400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cooperating gene mutations in childhood acute myeloid leukemia with special reference on mutations of ASXL1, TET2, IDH1, IDH2, and DNMT3A.
    Liang DC; Liu HC; Yang CP; Jaing TH; Hung IJ; Yeh TC; Chen SH; Hou JY; Huang YJ; Shih YS; Huang YH; Lin TH; Shih LY
    Blood; 2013 Apr; 121(15):2988-95. PubMed ID: 23365461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Model System for Studying the DNMT3A Hotspot Mutation (DNMT3A
    Lu R; Wang J; Ren Z; Yin J; Wang Y; Cai L; Wang GG
    Cancer Res; 2019 Jul; 79(14):3583-3594. PubMed ID: 31164355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutation and expression analysis of the IDH1, IDH2, DNMT3A, and MYD88 genes in colorectal cancer.
    Li WL; Xiao MS; Zhang DF; Yu D; Yang RX; Li XY; Yao YG
    Gene; 2014 Aug; 546(2):263-70. PubMed ID: 24887488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The combination of NPM1, DNMT3A, and IDH1/2 mutations leads to inferior overall survival in AML.
    Dunlap JB; Leonard J; Rosenberg M; Cook R; Press R; Fan G; Raess PW; Druker BJ; Traer E
    Am J Hematol; 2019 Aug; 94(8):913-920. PubMed ID: 31145495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA methylation and hydroxymethylation patterns in acute myeloid leukemia patients with mutations in DNMT3A and IDH1/2 and their combinations.
    Šestáková Š; Krejčík Z; Folta A; Cerovská E; Šálek C; Merkerová MD; Pecherková P; Ráčil Z; Mayer J; Cetkovský P; Remešová H
    Cancer Biomark; 2019; 25(1):43-51. PubMed ID: 30988238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution.
    Lin CC; Hou HA; Chou WC; Kuo YY; Liu CY; Chen CY; Lai YJ; Tseng MH; Huang CF; Chiang YC; Lee FY; Liu MC; Liu CW; Tang JL; Yao M; Huang SY; Ko BS; Wu SJ; Tsay W; Chen YC; Tien HF
    Am J Hematol; 2014 Feb; 89(2):137-44. PubMed ID: 24115220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.